An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
Status:
Completed
Trial end date:
2017-10-16
Target enrollment:
Participant gender:
Summary
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following
Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis